StreetAlpha.app
Home › Stocks › LENZ

LENZ Therapeutics, Inc. (LENZ)

Healthcare
$3.50
▼ −8.38%
LAST CLOSE · NOV 17

LENZ Therapeutics sells VIZZ, a daily eye drop that improves near vision for adults with presbyopia. It last closed at $3.50 on Nov 17, down 8.38% on the day. LENZ last reported earnings on Tue, Aug 11, 2026. The average 12-month price target from 4 analysts is $18.75 (+435.7% from the last close), with a high of $45.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell).

AI Auto Pilots
Is LENZ in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$12.4M
−29.4% vs a year ago
Net income
−$140.3M
−1135.0% margin
EPS (diluted)
−$4.53
Free cash flow
−$127.7M
−1033.3% margin
Valuation
Market cap
$110.0M
31.4M shares
P/E
–
No P/E while losing money
Price to sales
8.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$30.6M
At Sep 30
Shareholder equity
$192.0M
Shares outstanding
31.4M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $19.1M$19.1MFY2025

From LENZ's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Last report
Aug 11
2026 · After the close (AMC)
Reported EPS
-$1.02
vs -$1.21 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±13.7%
Priced in before that report
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
3 Buy1 Hold0 Sell
Each firm's latest rating on LENZ in the past 90 days
Average 12-month target
$18.75
▲ 435.7% upside

Based on 4 analysts who set a price target on LENZ in the past 90 days. The average target is $18.75, with a high of $45.00 and a low of $5.00, compared with the last close of $3.50.

Low $5.00Avg $18.75High $45.00
Blue marker: last close $3.50
Highest target$45.00
Average target$18.75
Lowest target$5.00
Latest rating changes
CitigroupMaintained
Nov 5Buy$9
HC Wainwright & Co.Target lowered
Oct 30Buy$38 → $16
TD CowenTarget lowered
Oct 29Buy$50 → $45
TD CowenMaintained
Oct 21Buy$50
Piper SandlerTarget lowered
Oct 19Hold$7 → $5
DateFirmActionRatingPrice target
Nov 5CitigroupMaintainedBuy$9
Oct 30HC Wainwright & Co.Target loweredBuy$38 → $16
Oct 29TD CowenTarget loweredBuy$50 → $45
Oct 21TD CowenMaintainedBuy$50
Oct 19Piper SandlerTarget loweredHold$7 → $5
Loading…

Technical Analysis

LENZ · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 0% below its 20 day and 6% below its 50 day average. It is 103% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 47). The nearest support is the swing low (Oct 8) at $3.35, and the nearest resistance the 20 day average at $3.51.

Short trendNeutral
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 9.7%/day
Key levels
$32.1352 week high+818.0%
$7.12200 day average+103.4%
$4.50100 day average+28.6%
$3.74Pivot R1+6.9%
$3.7250 day average+6.3%
$3.71Swing high (Nov 3)+6.0%
$3.59Pivot+2.6%
$3.5120 day average+0.3%
$3.50Last close
$3.35Swing low (Oct 8)−4.3%
$3.34Pivot S1−4.6%
$2.8052 week low−20.0%
Indicators
RSI (14)46.69Middle of its rangeNeutral
MACD0.07Above its signal lineBullish
Stochastic64.8Middle of its rangeNeutral
ADX (14)23.7Weak trend
Williams %R-55.4Oversold below −80, overbought above −20Neutral
CCI (20)17.3Oversold below −100, overbought above 100Neutral
Rate of change+0.0%Change over 10 sessionsBearish
ATR (14)$0.34Typical daily range, 9.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LENZ

What happened before

See how LENZ did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LENZ usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LENZ has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LENZ in the last 90 days.

Loading…

See today’s whale options flow across the market →

LENZ Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●67 buying vs 67 selling
  • ▼Held by funds -13.3 pts
  • ▼Funds holding -7
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding138145−4.8%
In funds' top 10330.0%
Held by funds97.4%110.7%−13.3 pts
New / increased18 / 4928 / 60−23.9%
Reduced / sold out40 / 2733 / 27+11.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LENZ institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LENZ is in one of them and how their past LENZ trades turned out.

LENZ in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LENZ in an article yet. Here's the latest on the wider market.

About LENZ Therapeutics

LENZ Therapeutics is a pharmaceutical company based in Solana Beach, California, that develops and sells treatments for eye conditions. Its main product is VIZZ, a daily eye drop that improves near vision for adults with presbyopia, the loss of close-up focus that comes with aging. The company sells VIZZ in the United States to eye care professionals such as optometrists and ophthalmologists, and to patients who buy it at retail pharmacies.

Headquarters
Solana Beach, CA